Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Protalix Biotherapeutics Inc    PLX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
07/19/2017 07/20/2017 07/21/2017 07/24/2017 07/25/2017 Date
0.77(c) 0.76(c) 0.74(c) 0.77(c) 0.78 Last
595 488 521 685 476 261 501 803 186 574 Volume
-2.53% -1.30% -2.63% +4.05% +1.30% Change
More quotes
Financials ($)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 35,8 M
EBIT 2014 -12,9 M
Net income 2014 -4,70 M
Debt 2014 -
Yield 2014 -
P/E ratio 2013 -
P/E ratio 2014
Capi. / Sales2013 6,18x
Capi. / Sales2014 2,72x
Capitalization 97,4 M
More Financials
Company
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system.It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease.Its drug... 
More about the company
Surperformance© ratings of Protalix Biotherapeutics I
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTALIX BIOTHERAPEUTICS I
10:28p Protalix BioTherapeutics Completes Private Note Exchange of $9 million Notes ..
07/22 PROTALIX BIOTHERAPEUTICS : Is Undervalued With Upcoming Catalysts
07/19 PROTALIX BIOTHERAPEUTICS : Today's Research Report Coverage on Biotech Stocks --..
07/01 PROTALIX BIOTHERAPEUTICS : ProCellEx Has The Potential To Upend The Biopharmaceu..
06/07 PROTALIX BIOTHERAPEUTICS, INC. : Other Events (form 8-K)
06/07 Protalix BioTherapeutics Announces Phase II Clinical Trial Results for alidor..
06/01 Protalix BioTherapeutics Announces FDA Approval to Operate its Current Facili..
06/01 PROTALIX BIOTHERAPEUTICS : Announces Presentation of Phase II Clinical Trial Res..
06/01 PROTALIX BIOTHERAPEUTICS : to Present at the Jefferies 2017 Global Healthcare Co..
05/25 Protalix BioTherapeutics to Present at the Jefferies 2017 Global Healthcare C..
More news
Sector news : Biotechnology & Medical Research - NEC
01:37pDJELI LILLY AND : to Delay Arthritis Drug Application -- Market Talk
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/12 FDA panel backs Novartis' pioneering new cancer gene therapy
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
More sector news : Biotechnology & Medical Research - NEC
Chart PROTALIX BIOTHERAPEUTICS I
Duration : Period :
Protalix Biotherapeutics I Technical Analysis Chart | PLX | US74365A1016 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 6,50 $
Spread / Average Target 744%
EPS Revisions
Managers
NameTitle
Moshe Manor President, Chief Executive Officer & Director
Shlomo Yanai Chairman
Tzvi Palash Chief Operating Officer
Yossi Maimon CFO, Secretary, Treasurer & Vice President
Yoseph Shaaltiel Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PROTALIX BIOTHERAPEUTICS INC66.29%97
INCYTE CORPORATION33.86%28 314
QUINTILES IMS HOLDINGS INC19.86%19 795
LONZA GROUP31.59%16 758
CELLTRION, INC.--.--%12 650
ALKERMES PLC5.49%8 982